

Applicants : Tove Ringerike et al.  
Serial No. : 10/577,268  
Filed : April 26, 2006  
Page : 7 of 8 of August 29, 2011 Supplemental  
Amendment

#### **REMARKS**

Claims 8 and 45-58 were pending in the subject application. By this Amendment, Applicants have amended claims 8, 45, 46 and 54 to correct errors in the SEQ ID NOs. recited therein and to correct typographical errors. Applicants have also amended Figures 3 and 5 to conform the plasmid sizes listed in the Figures to the plasmid sizes listed in the Sequence Listing. Accordingly, this Amendment introduces no new matter and Applicants respectfully request that this Amendment be entered.

#### **Summary of August 25, 2011 Telephone Conference**

On August 25, 2011 Examiner Hibbert telephoned the undersigned to discuss the subject application. Applicants acknowledge with appreciation the courtesy that Examiner Hibbert extended during the August 25, 2011 telephone conference. Applicants are submitting this Summary pursuant to 37 C.F.R. § 1.133(b).

During the August 25, 2011 telephone conference, the Examiner indicated that upon reviewing Applicants' June 16, 2011 Amendment, she noticed that the SEQ ID No. of each plasmid recited by the claims does not correspond to the SEQ ID No. of the same plasmid in the Sequence Listing. The Examiner also indicated that the plasmid sizes identified in the Figures do not correspond to the plasmid sizes identified in the Sequence Listing. Finally, the Examiner indicated that the subject application would be in condition for allowance once the subject application is amended to correct the inconsistencies between the claims, Figures, and Sequence Listing.

In response, Applicants thank the Examiner for her careful review of the subject application. Applicants have herein amended the subject application to correct the inconsistencies identified by

Applicants : Tove Ringerike et al.  
Serial No. : 10/577,268  
Filed : April 26, 2006  
Page : 8 of 8 of August 29, 2011 Supplemental  
Amendment


the Examiner. Specifically, Applicants have amended claims 8, 45, and 54 so that each recited plasmid is identified by same SEQ ID No. in both the claims and the Sequence Listing. Applicants have also amended Figures 3 and 5 so that the plasmid sizes indicated in each figure are the same as the plasmid sizes indicated in the Sequence listing.


Accordingly, Applicants believe that the subject application is in condition for allowance and look forward to receiving a Notice of Allowance.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

<b>Certificate of Transmission</b>	
I hereby certify that this correspondence is being transmitted via the Electronic Filing System (EFS) to the U.S. Patent and Trademark Office on <u>August 31, 2011</u> :	
	<u>8/31/11</u>
Adam C. Krol Reg. No. 64,351	Date

  
Gary J. Gerushik  
Registration No. 39,992  
Attorney for Applicants  
Cooper & Dunham LLP  
30 Rockefeller Plaza,  
20<sup>th</sup> Floor  
New York, New York 10112  
(212) 278-0400